Imagion Biosystems Announces Relocation Of U.S. Operations To San Diego

MELBOURNE, Australia, April 3, 2018 /PRNewswire/ -- Imagion Biosystems Limited (ASX:IBX), a company dedicated to improving healthcare through the earlier…


Late-Breaking MagSense™ Safety Study Abstract Accepted for AACR 2018

Imagion Biosystems' abstract "Detection of HER2+ tumor cells using MagSense™ nanoparticles: safety and sensitivity" has been accepted for the 2018 AACR meeting…


FY2017 Appendix 4E and Financial Report

Imagion Biosystems Limited Appendix 4E for the year ended 31 December 2017 has been lodged with ASX under Listing Rule 4.3A. Download FY 2017 Appendix 4E and…


Imagion Biosystems Appoints Dr Farideh Bischoff as Vice President of Clinical Research

Cancer diagnostics industry veteran will lead first-in-human clinical trial program Imagion Biosystems is pleased to announce the appointment of Farideh…


Notice of change of interests of substantial holder – IBX

Imagion Biosystems today announced "Notice of change of interests of substantial holder — IBX." View Form 604 Notice of change of interests of substantial…


Appendix 3B - Quotation of shares released from escrow

Imagion Biosystems today announced "Appendix 3B - Quotation of shares released from escrow." View Appendix 3B - Quotation of shares released from escrow.


Imagion Biosystems December 2017 Quarterly Update

In accord with ASX requirements, Imagion Biosystems' 2017 quarterly update was lodged with the Australian Securities Exchange on 31 January 2018. The update…


Release of shares from escrow

In accordance with Listing Rule 3.10A, Imagion Biosystems Limited (the Company) advises that 30,950,569 fully paid ordinary shares in the Company, which are…


December 2017 Investor Update Presentation Visuals

Click on image above or here to download presentation visuals for December 2017 investor update. (2MB pdf)